U.S. markets open in 5 hours 21 minutes
  • S&P Futures

    3,698.25
    -10.75 (-0.29%)
     
  • Dow Futures

    29,598.00
    -71.00 (-0.24%)
     
  • Nasdaq Futures

    11,348.50
    -28.25 (-0.25%)
     
  • Russell 2000 Futures

    1,681.00
    -5.10 (-0.30%)
     
  • Crude Oil

    78.41
    -0.33 (-0.42%)
     
  • Gold

    1,651.00
    -4.60 (-0.28%)
     
  • Silver

    18.64
    -0.27 (-1.43%)
     
  • EUR/USD

    0.9683
    -0.0005 (-0.05%)
     
  • 10-Yr Bond

    3.6970
    0.0000 (0.00%)
     
  • Vix

    31.70
    +4.35 (+15.90%)
     
  • GBP/USD

    1.0725
    -0.0131 (-1.21%)
     
  • USD/JPY

    143.7110
    +0.3910 (+0.27%)
     
  • BTC-USD

    18,959.74
    -144.84 (-0.76%)
     
  • CMC Crypto 200

    433.24
    -11.29 (-2.54%)
     
  • FTSE 100

    7,008.83
    -9.77 (-0.14%)
     
  • Nikkei 225

    26,431.55
    -722.28 (-2.66%)
     

Why Alzamend Neuro Stock Soared Today

·1 min read
Why Alzamend Neuro Stock Soared Today

Shares of Alzamend Neuro (NASDAQ: ALZN) surged 28% on Tuesday, as investors bought in ahead of the biotech's upcoming clinical data release for its experimental Alzheimer's treatment. Alzamend is an early stage biopharmaceutical company focused on creating therapies for neurodegenerative diseases and psychiatric conditions. Its investigational oral treatment for dementia related to Alzheimer's, AL001, has been shown to prevent cognitive impairment in mice. Alzamend is currently conducting a phase 1 human clinical study to evaluate the safety and proper dosing for AL001 in a planned phase 2 trial.